Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Voxcan logo — Animal Medical Imaging Services

Voxcan

Animal Medical Imaging Services

Founded 2007 France France 15 employees VR/AR

General Information

Company Name Voxcan
Founded Year 2007
Location France France +1
Employees 15
Industries VR/AR
Social

Get notified when Voxcan moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Voxcan

Voxcan is a Lyon, France based startup specializing in non-invasive high-resolution imaging for non-clinical drug development. With a 16-year track record, their core focus areas include oncology, viral and bacterial infectious diseases, osteo-articular inflammatory diseases, and medical devices. The company's expertise lies in conducting efficacy, biodistribution, mechanistic, and proof of concept studies based on in vitro and in vivo models combined with high-resolution imaging in small animal species. In July 2023, Voxcan became part of the ERBC group, broadening its service offerings and providing clients with access to a full range of non-clinical expertises. This acquisition aligns with ERBC's 3R policy, aiming to reduce the number of animals (up to 80%) used in non-clinical studies and improve animal welfare. Voxcan's capability to perform non-clinical studies up to Biosafety Level 3, meeting stringent safety and containment requirements in the infectious disease domain, is a testament to their commitment to scientific reliability and traceability. Moreover, Voxcan offers a wide variety of characterized tumor, bacterial, and viral models, including SARS-CoV-2, to test new compounds and cell therapies, as well as assess medical device performance and degradation. Their expertise in non-clinical 3D CT (computed tomography) imaging, 3D high-resolution imaging (µCT), and non-invasive bioluminescence and fluorescence imaging, combined with mechanistic analyses based on technologies such as flow cytometry, Luminex, and qPCR, enables longitudinal monitoring of compound efficacy and biodistribution. Ultimately, Voxcan aims to assist Pharma, Biotech, and Medical Device companies in accelerating the time-to-market of their candidate therapies by providing high-technology readouts. With a solid foundation since 2007 and strategic integration within the ERBC group, Voxcan is well-positioned to drive innovation and contribute meaningfully to the field of non-clinical drug development.

Taxonomy: Non-clinical drug development, High-resolution imaging, Oncology, Infectious diseases, Medical devices, Animal models, Biosafety Level 3, GLP guidelines, 3D CT imaging, Bioluminescence imaging, Fluorescence imaging, Pharma industry, Biotech industry, Data integrity, Animal welfare

No funding data available for Voxcan yet.

Get notified when Voxcan raises funding

FAQ About Voxcan

Animal Medical Imaging Services
Voxcan was founded in 2007.
Voxcan is headquartered in France.
Voxcan operates in the following industries: VR/AR.
Voxcan has approximately 15 employees.

We're actively collecting intelligence on Voxcan.

Track Voxcan to get notified

Don't just browse. Track.

Signal Tracker monitors Voxcan and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy